Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study-Reference-Cited by-同舟云学术

Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study

Published:2012-09 Issue:9 Volume:13 Page:936-945
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Biondi Andrea,Schrappe Martin,De Lorenzo Paola,Castor Anders,Lucchini Giovanna,Gandemer Virginie,Pieters Rob,Stary Jan,Escherich Gabriele,Campbell Myriam,Li Chi-Kong,Vora Ajay,Aricò Maurizio,Röttgers Silja,Saha Vaskar,Valsecchi Maria Grazia

Funder

Projet Hospitalier de Recherche Clinique-Cancer (France), Fondazione Tettamanti-De Marchi and Associazione Italiana per la Ricerca sul Cancro

Publisher

Elsevier BV

Subject

Oncology

Reference33 articles.

1. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia;Aricò;N Engl J Med,2000

2. Treatment of acute lymphoblastic leukemia;Pui;N Engl J Med,2006

3. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005;Aricò;J Clin Oncol,2010

4. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase;Schindler;Science,2000

5. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT–positive malignancies;Heinrich;J Clin Oncol,2002

Cited by 281 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOHO State of the Art Updates and Next Questions | Approach to BCR::ABL1-Like Acute Lymphoblastic Leukemia;Clinical Lymphoma Myeloma and Leukemia;2024-08

2. Case report: An intriguing case of Philadelphia chromosome–positive acute lymphoblastic leukemia recurrence;Frontiers in Oncology;2024-07-31

3. New Insights Into Infections’ Risk of Adolescents and Young Adults Treated for Acute Lymphoblastic Leukemia;Pediatric Infectious Disease Journal;2024-07-31

4. An Optimized Peptide Antagonist of CXCR4 Limits Survival of BCR–ABL1-Transformed Cells in Philadelphia-Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia;International Journal of Molecular Sciences;2024-07-30

5. Screening and interventional strategies for the late effects and toxicities of hematological malignancy treatments in pediatric survivors;Expert Review of Hematology;2024-06-25